Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Research

• Publication date

  2002-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12067989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

  2002cited by this paper
• Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis1

  2002cited by this paper
• Local Costimulation Reinvigorates Tumor-Specific Cytolytic T Lymphocytes for Experimental Therapy in Mice with Large Tumor Burdens1

  2001cited by this paper
• Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.

  2001cited by this paper
• 4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy1

  2001cited by this paper
• 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.

  2001cited by this paper
• Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.

  2000cited by this paper
• Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

  2000cited by this paper
• Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

  2000cited by this paper
• Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.

  2000cited by this paper
• 4-1BB Costimulation Is Required for Protective Anti-Viral Immunity After Peptide Vaccination1

  2000cited by this paper
• Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.

  2000cited by this paper
• Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.

  1999cited by this paper
• Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.

  1999influential reference
• 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.

  1999cited by this paper
• Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function

  1998cited by this paper
• Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

  1998cited by this paper
• Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors.

  1998cited by this paper
• NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

  1998influential reference
• 4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses

  1997influential reference
• Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.

  1997cited by this paper
• Costimulation of CD28- T lymphocytes by 4-1BB ligand.

  1997cited by this paper
• Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

  1997cited by this paper
• Determination of lymphocyte division by flow cytometry.

  1994cited by this paper
• T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells

  1994cited by this paper
• 4‐1BB T‐cell antigen binds to mature B cells and macrophages, and costimulates anti‐μ‐primed splenic B cells

  1994cited by this paper
• Inducible T cell antigen 4-1BB. Analysis of expression and function.

  1993cited by this paper

• The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes

  2022cites this paper
• Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

  2022cites this paper
• CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

  2021cites this paper
• Evaluation of immunomodulatory effects of Boswellia sacra essential oil on T-cells and dendritic cells

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity

  2020cites this paper
• Dendritic cell therapy in cancer treatment; the state-of-the-art.

  2020cites this paper
• Immunobiology of chimeric antigen receptor T cells and novel designs

  2019cites this paper
• Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule

  2019cites this paper
• The Role of T-cell Costimulation in the Pathogenesis of Kawasaki Disease

  2019cites this paper
• Driving cars to the clinic for solid tumors

  2018cites this paper
• The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

  2018cites this paper
• Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab.

  2018cites this paper
• Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines☆

  2017cites this paper
• Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia

  2017cites this paper
• The use of immunotherapy in the treatment of melanoma

  2017cites this paper
• A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

  2017cites this paper
• Dendritic cell-based immunotherapy: a basic review and recent advances

  2017cites this paper
• Memory Potential, Molecular Characterization, and Translational Applications of the Novel ThEO/TcEO T Cell Phenotype

  2017cites this paper
• Immunotherapy-based combinations: current status and perspectives

  2017cites this paper
• Selection of single chain antibody fragments binding to the extracellular domain of 4-1BB receptor by phage display technology

  2017cites this paper
• Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy

  2016cites this paper
• Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination

  2016cites this paper
• Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies

  2016cites this paper
• Immunotherapy of Melanoma.

  2016cites this paper
• Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

  2016cites this paper
• Cancer immunotherapy via nucleic acid aptamers.

  2015cites this paper
• Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

  2015cites this paper
• Eradication of established murine mesothelioma tumours by combined immunotherapy

  2015cites this paper
• 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

  2015cites this paper
• A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing

  2015cites this paper
• Immune checkpoint blockade and interferon-α in melanoma.

  2015cites this paper
• 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

  2014cites this paper
• Differential effects of agonistic 4-1BB (CD137) monoclonal antibody on the maturation and functions of hypoxic dendritic cells.

  2014cites this paper
• 4-1BB and the Epigenetic Regulations of This Molecule

  2014cites this paper
• 4-1BB Chimeric Antigen Receptors

  2014cites this paper
• Trial watch: IDO inhibitors in cancer therapy

  2014cites this paper
• Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

  2014cites this paper
• Immune co-signaling to treat cancer

  2013cites this paper
• Cancer Immunotherapy

  2013cites this paper
• Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma

  2013cites this paper
• Anti-4-1BB/4-1BBL

  2013cites this paper
• T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes

  2013cites this paper
• Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse

  2013cites this paper
• CHARACTERIZING THE EFFECT OF DASATINIB ON ANTI-TUMOR IMMUNE RESPONSE AND EXPLORING THE POTENTIAL OF COMBINING TARGETED THERAPY AND IMMUNOTHERAPY IN A C-KIT MUTANT MASTOCYTOMA MODEL

  2013cites this paper
• Polyubiquitin-Dependent Signals from - Monoclonal Antibodies Is Mediated by K63 T Cell Costimulation with Anti-CD137

  2013cites this paper
• Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137

  2013cites this paper
• Dendritic cell immunotherapy

  2013cites this paper
• Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells

  2012cites this paper
• Differential Requirement for CD 70 and CD 80 / CD 86 in Dendritic Cell-mediated Activation of Tumor Tolerized CD 8 T Cells

  2012cites this paper
• Activation of Tumor-Tolerized CD 8 T Cells CD 80 / CD 86 in Dendritic Cell-Mediated Differential Requirement for CD 70 and

  2012cites this paper
• Tráfico de células dendríticas a través de endotelio linfático en condiciones de inflamación

  2012cites this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cites this paper
• Immunotherapy of Cancer with 4-1BB

  2012cites this paper
• Dissecting the Role of 4-1BB and its Ligand in Enhancing CD8 Effector and Memory T Cell Responses

  2012cites this paper
• Treatment of Melanoma with Agonist Immune Costimulatory Agents

  2012cites this paper
• A Mathematical Model of Immune-System-Melanoma Competition

  2012cites this paper
• Immunotherapy of cancer in 2012

  2012cites this paper
• T-pharmacytes for Prostate Cancer Immunotherapy

  2012cites this paper
• Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

  2011cites this paper
• Cell-Specific Aptamers as Emerging Therapeutics

  2011cites this paper
• Immunotherapy for melanoma

  2011cites this paper
• Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.

  2011cites this paper
• Agonist Anti-CD 137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

  2011cites this paper
• Beyond Cancer Vaccines: A Reason for Future Optimism With Immunomodulatory Therapy

  2011cites this paper
• Harnessing Dendritic Cells for Tumor Antigen Presentation

  2011cites this paper
• SimB16: Modeling Induced Immune System Response against B16-Melanoma

  2011cites this paper
• Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.

  2010cites this paper
• CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

  2010cites this paper
• Immune Regulatory Antibodies: Are They the Next Advance?

  2010cites this paper
• Mature B Cells Are Critical to T-cell-mediated Tumor Immunity Induced by an Agonist Anti-GITR Monoclonal Antibody

  2010cites this paper
• Cancer vaccine development: designing tumor cells for greater immunogenicity.

  2010cites this paper
• Directing dendritic cell immunotherapy towards successful cancer treatment.

  2010cites this paper
• The Role of Costimulation in the Persistence of the Immune Response in Kawasaki Disease

  2010cites this paper
• A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1

  2009cites this paper
• Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors

  2009cites this paper
• Integrating costimulatory agonists to optimize immune-based cancer therapies.

  2009cites this paper
• Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer

  2009cites this paper
• Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

  2009cites this paper
• Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists

  2009cites this paper
• Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration

  2009cites this paper
• Lymphocytes and Antitumor Activity Leads to Enhanced Survival of Transduced T Receptor with Modified Signaling Domains A Herceptin-Based Chimeric Antigen

  2009cites this paper
• In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb

  2009cites this paper
• Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

  2009cites this paper
• Twelve immunotherapy drugs that could cure cancers.

  2008cites this paper
• Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule.

  2008cites this paper
• Analysis of CD137 and CD137L expression in human primary tumor tissues.

  2008cites this paper
• Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice

  2008cites this paper
• Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

  2008cites this paper
• Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines

  2008cites this paper
• Overcoming immune evasion in T cell therapy of cancer: lessons from animal models.

  2008cites this paper
• CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response

  2008cites this paper
• Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.

  2007cites this paper
• General Principles of Tumor Immunotherapy

  2007cites this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cites this paper
• Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.

  2007cites this paper
• Multivalent 4-1 BB binding aptamers costimulate CD 8 + T cells and inhibit tumor growth in mice

  2007cites this paper
• Development of anti-PAX3 immune responses; a target for cancer immunotherapy

  2007cites this paper
• Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.

  2007cites this paper
• Immunotherapy and Cancer Therapeutics: Why Partner?

  2007cites this paper